Applied Filters
LSIPR 50 2017: Paul Nurse
Paul Nurse was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: Michael Salzmann
Michael Salzmann was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.
LSIPR 50 2017: Marcus Dalton
Marcus Dalton was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Galit Gonen
Galit Gonen was selected in the LSIPR 50 2017 publication for her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Mr Justice Richard Arnold
Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
LSIPR 50 2017: Jörg Thomaier
Jörg Thomaier was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.
Case report: diagnostics in Germany
In September 2016, the German Federal Supreme Court decided a patent case that could have a major impact on companies working in the diagnostics field. Joachim Wachenfeld of Vossius & Partner reports.
Raising the plausibility bar
Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.
Plausibility: How much information is enough?
Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.
After Brexit: new directions for clinical trials
If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.
